Ulrich Grädler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ulrich Grädler has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Birgitta Leuthner
The healthcare business of Merck KGaA, Darmstadt, Germany
27 shared publications - Andreas Blum
The Healthcare Business of Merck KGaA , Frankfurter Strasse 250
26 shared publications - Christina Esdar
The healthcare business of Merck KGaA, Darmstadt, Germany
26 shared publications - Nina Linde
The healthcare business of Merck KGaA, Darmstadt, Germany
26 shared publications - Andree Blaukat
Translational Innovation Platform Oncology and Immuno-Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany
25 shared publications - Carl Petersson
The healthcare business of Merck KGaA, Darmstadt, Germany
25 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10220
PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12
Phosphoinositide 3-kinases (PI3Ks) are major regulators of cell growth, proliferation and signalling, constituting key therapeutic targets in cancer, inflammation, and other diseases. Individual class I PI3K isoforms control key cellular functions, imposing the need to generate isoform-specific inhibition for therapeutic intervention. Roginolisib is a selective PI3Kδ inhibitor that shows promise for the treatment of cancer. Using a combination of X-ray crystallography, molecular dynamics simulations, and hydrogen-deuterium exchange mass spectrometry, we describe the mechanism driving roginolisib’s potent and isoform-selective inhibition of PI3Kδ. Roginolisib uniquely stabilises the catalytic C-terminal helix kα12, locking the enzyme in an inactive conformation. This binding mode also results in more sustained inhibition of phosphatidylinositol 3,4,5-trisphosphate formation in tumour samples of CLL patients. Inhibition of PI3Ks by stabilization of helix kα12 into an inactive conformation has not, to the best of our knowledge, been described before and may provide the basis for novel, more selective and effective pharmacological strategies.
- 9 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10220
Open AccessPI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12
Phosphoinositide 3-kinases (PI3Ks) are major regulators of cell growth, proliferation and signalling, constituting key therapeutic targets in cancer, inflammation, and other diseases. Individual class I PI3K isoforms control key cellular functions, imposing the need to generate isoform-specific inhibition for therapeutic intervention. Roginolisib is a selective PI3Kδ inhibitor that shows promise for the treatment of cancer. Using a combination of X-ray crystallography, molecular dynamics simulations, and hydrogen-deuterium exchange mass spectrometry, we describe the mechanism driving roginolisib’s potent and isoform-selective inhibition of PI3Kδ. Roginolisib uniquely stabilises the catalytic C-terminal helix kα12, locking the enzyme in an inactive conformation. This binding mode also results in more sustained inhibition of phosphatidylinositol 3,4,5-trisphosphate formation in tumour samples of CLL patients. Inhibition of PI3Ks by stabilization of helix kα12 into an inactive conformation has not, to the best of our knowledge, been described before and may provide the basis for novel, more selective and effective pharmacological strategies.
- Open Access
- 4 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18277-18299
Fragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8
Human DHX8 is a spliceosomal DEAH-box RNA helicase involved in releasing mRNA from the spliceosome and crucial in ensuring splicing fidelity. DHX8 was identified as a promising therapeutic oncology target due to its role in regulating stress-adaptive gene expression, including HSF1-dependent transcription, while having broader transcriptional effects in cells under oncogenic stress. We report the discovery of novel RNA-competitive DHX8 inhibitors based on a 2-(phenethylthio)nicotinic acid scaffold, which were optimized using a structure-guided design approach, following a biophysical fragment screen. This yielded compound 53 with nanomolar biochemical potency, good in vitro PK, and activity in a cellular target engagement assay. Optimizing inhibitor binding between Arg647 and the nonconserved His693, coupled with extending into a pocket in the DHX8 Winged-Helix domain, was crucial for potency improvement. By binding in the Winged-Helix domain, these inhibitors restrict the helicase domain’s conformational plasticity, stabilizing a closed, inactive conformation while sterically blocking ssRNA translocation.
- 4 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18277-18299
Open AccessFragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8
Human DHX8 is a spliceosomal DEAH-box RNA helicase involved in releasing mRNA from the spliceosome and crucial in ensuring splicing fidelity. DHX8 was identified as a promising therapeutic oncology target due to its role in regulating stress-adaptive gene expression, including HSF1-dependent transcription, while having broader transcriptional effects in cells under oncogenic stress. We report the discovery of novel RNA-competitive DHX8 inhibitors based on a 2-(phenethylthio)nicotinic acid scaffold, which were optimized using a structure-guided design approach, following a biophysical fragment screen. This yielded compound 53 with nanomolar biochemical potency, good in vitro PK, and activity in a cellular target engagement assay. Optimizing inhibitor binding between Arg647 and the nonconserved His693, coupled with extending into a pocket in the DHX8 Winged-Helix domain, was crucial for potency improvement. By binding in the Winged-Helix domain, these inhibitors restrict the helicase domain’s conformational plasticity, stabilizing a closed, inactive conformation while sterically blocking ssRNA translocation.
- Open Access
- 23 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 360, 151496
Structure-based design of pyrazole derivatives targeting the human Cyclophilin D binding site
- 23 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 360, 151496
Open AccessStructure-based design of pyrazole derivatives targeting the human Cyclophilin D binding site
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Discovery of M4205, a potent inhibitor of disease-relevant KIT-mutant variants. A, Schematic overview of clinically observed mutations in different domains of the RTK KIT and estimated target coverage (green: positive; red: negative) of approved and investigational KIT inhibitors. 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line. B, X-ray structures of M4205 (2.1 Å resolution; PDB ID: 7ZW8) in complex with the kinase domain of wild-type KIT. For clarity, only interacting residues are shown including H-bonds and Van der Waals contacts (depicted as dashed black and brown lines, respectively). C, Potent biochemical inhibition of clinically relevant KIT mutations in exon 11, exon 13/14, and exon 17 is demonstrated for M4205 compared with approved KIT inhibitors imatinib, sunitinib, and ripretinib. IC50 values show mean with SD of two technical replicates. D, Cellular target engagement of KIT-mutant forms with M4205 is confirmed in NanoBRET assays. Target coverage is determined by competitive displacement of the NanoBRET tracer with 1, 10, or 100 nmol/L M4205 and is shown as mean with SD of two technical replicates.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Discovery of M4205, a potent inhibitor of disease-relevant KIT-mutant variants. A, Schematic overview of clinically observed mutations in different domains of the RTK KIT and estimated target coverage (green: positive; red: negative) of approved and investigational KIT inhibitors. 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line. B, X-ray structures of M4205 (2.1 Å resolution; PDB ID: 7ZW8) in complex with the kinase domain of wild-type KIT. For clarity, only interacting residues are shown including H-bonds and Van der Waals contacts (depicted as dashed black and brown lines, respectively). C, Potent biochemical inhibition of clinically relevant KIT mutations in exon 11, exon 13/14, and exon 17 is demonstrated for M4205 compared with approved KIT inhibitors imatinib, sunitinib, and ripretinib. IC50 values show mean with SD of two technical replicates. D, Cellular target engagement of KIT-mutant forms with M4205 is confirmed in NanoBRET assays. Target coverage is determined by competitive displacement of the NanoBRET tracer with 1, 10, or 100 nmol/L M4205 and is shown as mean with SD of two technical replicates.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Dose- and exposure-dependent inhibition of KIT autophosphorylation with M4205 in the GIST430/654 model. A, Tumor-bearing mice were treated daily with three different doses of M4205 for 5 days, and inhibition of KIT autophosphorylation compared with untreated controls was determined at different time points after last treatment. B, Free plasma concentrations of M4205 were plotted against the effect of KIT inhibition which revealed an in vivo IC50 of 4 nmol/L. C–E, Inhibition of KIT autophosphorylation is correlated with free plasma concentration over time for the three dosage groups (dashed line: 4 nmol/L free in vivo IC50; dotted line: 16 nmol/L free cellular IC50).
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Dose- and exposure-dependent inhibition of KIT autophosphorylation with M4205 in the GIST430/654 model. A, Tumor-bearing mice were treated daily with three different doses of M4205 for 5 days, and inhibition of KIT autophosphorylation compared with untreated controls was determined at different time points after last treatment. B, Free plasma concentrations of M4205 were plotted against the effect of KIT inhibition which revealed an in vivo IC50 of 4 nmol/L. C–E, Inhibition of KIT autophosphorylation is correlated with free plasma concentration over time for the three dosage groups (dashed line: 4 nmol/L free in vivo IC50; dotted line: 16 nmol/L free cellular IC50).
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Mouse PK and human dose prediction
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Mouse PK and human dose prediction
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Biochemical inhibition of KIT variants
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Biochemical inhibition of KIT variants
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Split of M4205 concentration and FLT3 inhibition
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Split of M4205 concentration and FLT3 inhibition
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo antitumor activity of M4205 in xenograft models expressing oncogenic KIT mutations. Tumor bearing mice were treated daily with M4205 by oral gavage at doses indicated (10 mice per group). Body weight of mice was measured daily, and tumor growth was followed twice weekly. A, Exon 11–mutant GIST CDX model GIST430 (del560-576). B, Exon 11–mutant GIST PDX model (GS11342 and WKV557fs). C, Exon 11–mutant (del560-576) and exon 13–mutant (V654A) GIST CDX model GIST430/654. D, Exon 11–mutant (WK557del) and exon 13–mutant (V654A) GIST PDX model GS11331. E, Exon 11–mutant (WK557del) and exon 17–mutant (Y823D) GIST PDX model GS5108. F, Exon 17–mutant (N822K) AML CDX model Kasumi-1. Different letters within the graph indicate statistical significance (P < 0.05) according to two-way ANOVA analysis on log-transformed data. G, Treatment effects (%) for these different studies were plotted as T/C ratios. According to preclinical RECIST criteria, T/C ratios between 73% and −66% indicate tumor stasis and T/C ratios below −66% indicate tumor regression.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo antitumor activity of M4205 in xenograft models expressing oncogenic KIT mutations. Tumor bearing mice were treated daily with M4205 by oral gavage at doses indicated (10 mice per group). Body weight of mice was measured daily, and tumor growth was followed twice weekly. A, Exon 11–mutant GIST CDX model GIST430 (del560-576). B, Exon 11–mutant GIST PDX model (GS11342 and WKV557fs). C, Exon 11–mutant (del560-576) and exon 13–mutant (V654A) GIST CDX model GIST430/654. D, Exon 11–mutant (WK557del) and exon 13–mutant (V654A) GIST PDX model GS11331. E, Exon 11–mutant (WK557del) and exon 17–mutant (Y823D) GIST PDX model GS5108. F, Exon 17–mutant (N822K) AML CDX model Kasumi-1. Different letters within the graph indicate statistical significance (P < 0.05) according to two-way ANOVA analysis on log-transformed data. G, Treatment effects (%) for these different studies were plotted as T/C ratios. According to preclinical RECIST criteria, T/C ratios between 73% and −66% indicate tumor stasis and T/C ratios below −66% indicate tumor regression.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Cellular P-ERK1/2 and P-AKT inhibition
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Cellular P-ERK1/2 and P-AKT inhibition